Literature DB >> 10412897

Effect of tacrine hydrochloride on hepatic drug metabolism.

T C Danbury1, M Eccles, J Ford, C J Roberts.   

Abstract

The aim was to assess tacrine hydrochloride (THA) as an inhibitor of rat hepatic oxidative enzymes. A model of hepatic microsome oxidative metabolism was established using antipyrine (AP) incubated with NADPH. AP and its metabolites, 3-hydroxymethyl antipyrine (HMA). 4-hydroxy antipyrine (OHA) and norantipyrine (NORA) were measured by high performance liquid chromatography (HPLC). Aliquots of 200, 400 and 600 microg/ml antipyrine were incubated with the microsomal preparation alone, with 20 microg/ml cimetidine or with 40, 80 or 200 microg/ml THA. Cimetidine inhibited HMA production by 35-38% (P<0.001) and OHA production by 49-52% (P<0.001). Incubation with the 3 concentrations of THA inhibited HMA production by 17%, 24% and 41% (P<0.001) and OHA production by 52%, 55% and 79%, respectively (P<0.001). NORA was identifiable when antipyrine was incubated with NADPH alone, but could not be identified after incubation with either cimetidine or THA. This study has shown that THA causes the inhibition of AP metabolism to HMA, OHA and possibly NORA. We suggest THA is an inhibitor of three different hepatic microsomal cytochrome P-450 enzyme sub-families.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412897     DOI: 10.1007/BF03190016

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  27 in total

1.  Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.

Authors:  M F Murphy; S T Hardiman; R J Nash; F J Huff; J J Demkovich; C Dobson; U E Knappe
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

Review 2.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

3.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

4.  Antipyrine metabolism in the rat by three hepatic monooxygenases.

Authors:  T Inaba; M Lucassen; W Kalow
Journal:  Life Sci       Date:  1980-06-09       Impact factor: 5.037

5.  Effects of cimetidine and ranitidine on hepatic drug metabolism.

Authors:  K J Breen; R Bury; P V Desmond; M L Mashford; B Morphett; B Westwood; R G Shaw
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

6.  The effect of age on the oxidative metabolism of antipyrine by uninduced microsomal fractions of rat liver.

Authors:  C A Van Geel; C F Van Bezooijen
Journal:  Mech Ageing Dev       Date:  1990-04-09       Impact factor: 5.432

Review 7.  Pharmacokinetic drug interactions with theophylline.

Authors:  J H Jonkman; R A Upton
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

8.  The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes.

Authors:  V Spaldin; S Madden; W F Pool; T F Woolf; B K Park
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

9.  Comparison of rate of hepatic metabolism in vitro and half-life for antipyrine in vivo in three species.

Authors:  M E McManus; K F Ilett
Journal:  Xenobiotica       Date:  1979-02       Impact factor: 1.908

10.  Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.

Authors:  P B Watkins; H J Zimmerman; M J Knapp; S I Gracon; K W Lewis
Journal:  JAMA       Date:  1994-04-06       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.